NASDAQ$RVPH
Reviva Pharmaceuticals Holdi · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Reviva Pharmaceuticals reported fiscal 2024 net loss of $29.9M ($0.90 per share) with no product revenue.
For the year ended December 31, 2024, Reviva had no commercial revenue. Net loss was approximately $29.9 million ($0.90 per share) versus $39.3 million ($1.65) in 2023. Cash and equivalents were approximately $13.5 million. The company highlighted brilaroxazine Phase 3 RECOVER OLE data and plans to initiate registrational RECOVER-2 in mid-2025.
- FY2024 net loss $29.9M; EPS loss $0.90.
- Cash ~$13.5M at year-end.
- Brilaroxazine OLE showed sustained 1-year schizophrenia efficacy.
- Targeting NDA submission in Q4 2026 subject to financing.
Headline financials
Revenue & EPS history
Reviva · Revenue · Quarterly
$0
Forward guidance
Pre-commercial biotech; outlook tied to clinical milestones, partnerships, and capital raises rather than product revenue.
Tailwinds
- Pipeline milestones and collaboration funding can extend runway.
- Lower burn or narrowed losses when R&D timing shifts.
Headwinds
- No product sales; dilution risk from equity raises.
- Clinical and regulatory setbacks could impair financing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-1.2%
Avg return
Earnings day
-0.5%
Avg return
5 days after
+16.7%
Avg return
30 days after
39%
11 / 28 earnings
Positive
+15.8%
Q2 2025
Best reaction
-22.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +9.6% | +13.7% | +94.3% | |
| Q3 2025 | -7.3% | -7.9% | +23.0% | |
| Q2 2025 | +15.8% | +11.4% | -5.1% | |
| Q1 2025 | +4.9% | +31.6% | -8.1% | |
| Q4 2024 | +15.0% | +16.0% | +17.1% | |
| Q3 2024 | -9.6% | +0.8% | +108.8% | |
| Q1 2024 | +0.6% | -1.8% | -11.8% | |
| Q4 2023 | -9.8% | -18.2% | -53.7% | |
| Q3 2023 | -17.2% | -33.6% | -37.1% | |
| Q2 2023 | +3.4% | +0.0% | +28.8% | |
| Q1 2023 | +5.4% | -0.5% | -15.6% | |
| Q4 2022 | -10.1% | -5.2% | +47.0% | |
| Q3 2022 | -22.9% | -9.5% | -21.6% | |
| Q2 2022 | +2.8% | +4.9% | +208.5% | |
| Q1 2022 | +15.3% | +17.1% | -20.4% | |
| Q4 2021 | +0.0% | -3.3% | +21.1% | |
| Q3 2021 | -1.3% | -10.3% | -11.4% | |
| Q2 2021 | -6.0% | -4.9% | +18.3% | |
| Q1 2021 | -0.2% | +12.2% | -1.2% | |
| Q4 2020 | -22.3% | -22.6% | -46.5% | |
| Q3 2020 | -0.7% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | +0.1% | — | — | |
| Q4 2019 | +0.0% | — | — | |
| Q3 2019 | +0.0% | — | — | |
| Q2 2019 | +0.4% | — | — | |
| Q1 2018 | -0.1% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro